Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Trial Profile

Pivotal phase III trial of ALZ 801 in patients with Alzheimer's disease positive for e4 allele of the apolipoprotein E

Planning
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs ALZ 801 (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Alzheon
  • Most Recent Events

    • 24 Oct 2016 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017, according to an Alzheon media release.
    • 25 Jul 2016 According to an Alzheon media release, this trial is expected to start in early 2017.
    • 09 Sep 2015 According to an Alzheon media release, this trial is expected to start in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top